Trastuzumab RP plus chemotherapy is the standard of care for patients with HER2-positive breast cancers and approved in many countries for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer [1, 2, 4–6]. This evidence concerns the gene ERBB2 and breast carcinoma.